Back to top

biotechs: Archive

Ahan Chakraborty

4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day

LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.

NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change

Kevin Cook

Bear of the Day: Boston Scientific (BSX)

BSX growth continues to flatline but expects 2027 to mark cycle's trough, 2028 recovery driven by new launches

BSXPositive Net Change

Sundeep Ganoria

How Did AbbVie's Immunology Franchise Fare in Q3?

ABBV's immunology sales rose 16.6% in Q3, driven by Skyrizi and Rinvoq growth, prompting higher 2026 sales forecasts despite Humira's decline.

ABBVNegative Net Change JNJNegative Net Change LLYNegative Net Change

Sundeep Ganoria

MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?

Moderna's 3% post-earnings gain reflects stronger overseas COVID-19 sales and higher 2026 guidance, while oncology advances offer growth potential.

MRNANegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change

Zacks Equity Research

REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?

Regeneron's strong Eylea HD and Dupixent sales, expanding oncology portfolio and promising pipeline fuel growth prospects as Eylea faces intensifying competition.

REGNNegative Net Change

Ekta Bagri

Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?

GILD's HIV franchise gains momentum as Yeztugo sales surge, Biktarvy maintains market leadership and an expanding pipeline strengthens long-term growth prospects.

GILDNegative Net Change GSKNegative Net Change MRKNegative Net Change

Zacks Equity Research

Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief

ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.

ZTSPositive Net Change ADPTNo Net Change ACIUNegative Net Change AMRXPositive Net Change

Zacks Equity Research

ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?

ADMA Biologics gains 20.9% after strong Q3 results, as surging Asceniv sales and a raised 2026 profit outlook offset Bivigam weakness and competitive pressures.

ADMAPositive Net Change GRFSNegative Net Change TAKNegative Net Change

Zacks Equity Research

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth.

LQDAPositive Net Change UTHRNegative Net Change COLLPositive Net Change AMRXPositive Net Change

Zacks Equity Research

MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV

Mirum's brelovitug marks a second phase III win in chronic HDV, bringing the company closer to a planned 2027 BLA filing with the FDA.

MIRMNegative Net Change COLLPositive Net Change VCELPositive Net Change AMRXPositive Net Change